Haupt Pharma Gruppe

Haupt Pharma Gruppe is a contract manufacturing organization specializing in pharmaceutical and healthcare sectors, providing a variety of product formulations and packaging solutions designed to meet client needs globally. Founded in 2000 and headquartered in Berlin, Germany, Haupt Pharma Gruppe operates as a contract manufacturer for pharmaceutical companies. The company was acquired by Aenova Holding GmbH in October 2013, marking a strategic shift in its operational framework. The founder's history is not explicitly documented; however, the company is noted for its focused approach towards enhancing service offerings in the pharmaceutical market.

Haupt Pharma Gruppe specializes in contract manufacturing, delivering a broad range of pharmaceutical products including solid dosage forms, liquid formulations, and specialized delivery systems. Its services are tailored to meet the needs of clients in the medication and supplement markets, ensuring high-quality standards and regulatory compliance. The company serves clients across Europe, North America, and select Asian markets, frequently partnering with major pharmaceutical companies and healthcare providers to address various health-related issues. In the most recent financial year, Haupt Pharma Gruppe reported revenue of EUR 25,003,362.

4 and an EBITDA of EUR 1,088,206. 4, reflecting its strong business-to-business model that engages pharmaceutical firms and healthcare organizations in customized product manufacturing. Haupt Pharma Gruppe aims to enhance its market presence by expanding its product offerings and entering new geographical markets. Following its acquisition by Aenova Holding GmbH, the company will leverage recent funding to develop new pharmaceutical formulations and enhance its manufacturing capabilities.

The company is targeting expansion into emerging markets in Asia and Latin America, seeking to establish operational facilities by late 2014. The acquisition deal completed in October 2013 is expected to support these initiatives by providing additional resources for product development and market entry.